Patents by Inventor Hsi-Ming Lee
Hsi-Ming Lee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210322346Abstract: A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.Type: ApplicationFiled: June 21, 2021Publication date: October 21, 2021Applicants: The Research Foundation for The State University of New York, Chem-Master International Inc.Inventors: Ying Gu, Hsi-ming Lee, Lorne M. Golub, Francis Johnson, Guirong Wang, Osama Abdel-Razek, Yongan Xu
-
Publication number: 20180036262Abstract: A method of increasing production of one or more lipoxins in a subject in need thereof comprising administering to the subject an amount of a compound having the structure: or a pharmaceutically acceptable salt or ester thereof, so as to thereby increase production of the one or more lipoxins in the subject.Type: ApplicationFiled: March 10, 2016Publication date: February 8, 2018Applicants: The Research Foundation for the State University of New York, Chem-Master International Inc.Inventors: Ying Gu, Hsi-ming Lee, Lorne M. Golub, Francis Johnson, Guirong Wang, Osama Abdel-Razek, Yongan Xu
-
Publication number: 20160355465Abstract: This invention provides a compound having the structure wherein ?, ?, A, B, and R1-R4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.Type: ApplicationFiled: August 18, 2016Publication date: December 8, 2016Applicants: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK, CHEM-MASTER INTERNATIONAL, INC.Inventors: Lorne M. GOLUB, Hsi-ming LEE, Francis JOHNSON
-
Publication number: 20140275271Abstract: This invention provides a compound having the structure wherein ?, ?, A, B, and R1-R4 are defined herein. This invention also provides pharmaceutical compositions comprising the above compounds, a method of accelerating the healing of a wound, a method of inhibiting the activity and/or levels of a matrix metalloproteinase (MMP), a method of inhibiting the production of a cytokine in a population of cells, a method of inhibiting the production of a growth factor in a population of cells, and a method of inhibiting NF?-B activation in a population of cells.Type: ApplicationFiled: October 16, 2012Publication date: September 18, 2014Applicants: The Research Foundation for the State University of New York, Chem-Master International, Inc.Inventors: Lorne M. Golub, Hsi-ming Lee, Francis Johnson
-
Publication number: 20080249072Abstract: The invention is a method for reducing the production of inflammatory mediators, and/or treating conditions characterized by increased levels of inflammatory mediators, in a mammal in need thereof, by administering a 4-dedimethlaminosancycline to the mammal.Type: ApplicationFiled: September 21, 2005Publication date: October 9, 2008Inventors: Lorne M. Golub, Maria Emanuel Ryan, Hsi Ming Lee
-
Publication number: 20050282786Abstract: The present invention is for a method for decreasing C-reactive protein levels (CRP) in a mammal in need thereof. The method comprises administering an effective amount of a non-antibacterial tetracycline formulation, to the mammal. In one embodiment, the non-antibacterial tetracycline formulation is a non-antibacterial amount of an antibacterial tetracycline. In another embodiment, the non-antibacterial tetracycline formulation is a non-antibacterial tetracycline.Type: ApplicationFiled: July 11, 2003Publication date: December 22, 2005Inventors: David Brown, Lorne Golub, Hsi-Ming Lee, Robert Greenwald
-
Publication number: 20050148552Abstract: A method of treating eczema in a human or other mammal in need thereof comprising administering systemically to said human or other mammal a tetracycline compound in an amount that is effective to treat eczema, but has substantially no antibacterial activity.Type: ApplicationFiled: November 5, 2004Publication date: July 7, 2005Inventors: Maria Ryan, Yu Liu, Lorne Golub, Hsi-Ming Lee, Sanford Simon, Stephen Walker
-
Patent number: 6841547Abstract: The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.Type: GrantFiled: February 28, 2003Date of Patent: January 11, 2005Assignees: Albert Einstein College of Medicine of Yeshevia University, Montefiore Medical Center, The Research Foundation of State University of New YorkInventors: David Brown, Lorne M. Golub, Hsi-Ming Lee, Robert Greenwald, Maria Ryan, Kavita Desai
-
Publication number: 20040171591Abstract: The present invention relates to a method for decreasing elevated serum/plasma LDL-cholesterol levels or LDL-cholesterol levels and CRP levels in a mammal in need thereof. The methods comprises administering an effective amount of a tetracycline formulation. In one embodiment, the tetracycline formulation is a non-antibacterial tetracycline. In another embodiment, the tetracycline formulation is an antibacterial tetracycline at a sub-antibacterial amount.Type: ApplicationFiled: February 28, 2003Publication date: September 2, 2004Inventors: David Brown, Lorne M. Golub, Hsi-Ming Lee, Robert Greenwald, Maria Ryan, Kavita Desai
-
Publication number: 20040092491Abstract: The invention is method for preventing sepsis-induced ARDS in a mammal in need thereof, the method comprises administering to the mammal a tetracycline compound in an amount that is effective to prevent sepsis-induced ARDS but has substantially no antibiotic activity.Type: ApplicationFiled: November 9, 2002Publication date: May 13, 2004Applicant: The Research Foundation of State University of New YorkInventors: Gary Nieman, Sanford R. Simon, Lorne M. Golub, Hsi-Ming Lee, Jay Steinberg, Henry Schiller, Jeff Halter, Anthony Picone, William Marx, Louis Gatto, Charles Lutz
-
Patent number: 6429204Abstract: The invention is a method of inhibiting a sarcoma, such as Kaposi's sarcoma, in a mammal. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3.Type: GrantFiled: April 3, 2000Date of Patent: August 6, 2002Assignee: University of MiamiInventors: Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block
-
Publication number: 20020045603Abstract: The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) or 6-&agr;-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8) to inhibit the MT-MMP activity.Type: ApplicationFiled: May 14, 2001Publication date: April 18, 2002Applicant: The Research Foundation of State University of New YorkInventors: Lorne M. Golub, Hsi-Ming Lee, Timo Sorsa, Olli Teronen, Tuula Salo
-
Patent number: 6277061Abstract: The invention is a method of inhibiting the activity of membrane-type matrix metalloproteinase (MT-MMP) in biological systems. Accordingly, the invention permits the treatment of medical conditions in mammals that are characterized by MT-MMP activity, and especially those conditions characterized by excessive MT-MMP activity. The method employs a tetracycline compound, preferably a non-antimicrobial tetracycline, and more preferably 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) or 6-&agr;-deoxy-5-hydroxy-4-de(dimethylamino)tetracycline (CMT-8) to inhibit the MT-MMP activity.Type: GrantFiled: March 31, 1998Date of Patent: August 21, 2001Assignee: The Research Foundation of State University of New YorkInventors: Lorne M. Golub, Hsi-Ming Lee, Timo Sorsa, Olli Teronen, Tuula Salo
-
Patent number: 6100248Abstract: The invention is a method of inhibiting cancer growth, by inhibiting cellular proliferation, invasiveness, or metastasis, or by inducing cytotoxicity against cancer in mammals. The method employs 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.Type: GrantFiled: January 15, 1998Date of Patent: August 8, 2000Inventors: Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block
-
Patent number: 6015804Abstract: The invention is a method of enhancing endogenous interleukin-10 production in mammalian cells and tissues, which includes administering an effective amount of a tetracycline derivative. The method also includes enhancing interleukin-10 production by administering an effective amount of the tetracycline derivative to a mammal. Preferred tetracycline compounds are tetracycline compounds which have been modified to reduce or eliminate their antimicrobial activity. The method can be used to treat medical conditions in mammals characterized by excessive IL-1 and TNF .alpha. production.Type: GrantFiled: September 11, 1998Date of Patent: January 18, 2000Assignees: The Research Foundation of State University of New York, University of RochesterInventors: Lorne M. Golub, Christopher T. Ritchlin, Robert A. Greenwald, Sally Haas-Smith, Susan A. Moak, Hsi-Ming Lee
-
Patent number: 5837696Abstract: The invention is a method of inhibiting cancer growth, including cellular proliferation, invasiveness, or metastasis in mammals. The method employs 6-demethyl-6-deoxy-4-dedimethylaminotetracycline (CMT-3) and other functionally related chemically modified, preferably non-antibacterial, tetracycline compounds to inhibit cancer growth. The method is particularly effective to inhibit the establishment, growth, and metastasis of solid tumors, such as tumors derived from colon cancer cells, breast cancer cells, melanoma cells, prostatic carcinoma cells, or lung cancer cells.Type: GrantFiled: January 15, 1997Date of Patent: November 17, 1998Assignees: The Research Foundation of State University of New York, University of MiamiInventors: Lorne M. Golub, Thomas F. McNamara, Nungavaram S. Ramamurthy, Hsi-Ming Lee, Sanford Simon, Balakrishna L. Lokeshwar, Marie G. Selzer, Norman L. Block